Encorafenib
产品说明书
 |
同义名 : | LGX818 |
| CAS号 : | 1269440-17-6 | |
| 货号 : | A312190 | |
| 分子式 : | C22H27ClFN7O4S | |
| 纯度 : | 99%+ | |
| 分子量 : | 540.011 | |
| MDL号 : | MFCD25976758 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(92.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. Among them, B-RAF is the most frequently mutated protein kinase in human cancers. Encorafenib is a potent and selective B-RafV600E inhibitor, with no significant activity observed against a panel of 100 kinases (IC50>900nM). Encorafenib suppressed p-ERK with EC50 value of 3nM as well as led to potent inhibition of proliferation with EC50 value of 4nM in A375 cells (B-RafV600E), and did not inhibit proliferation of >400 cell lines expressing wild-type BRAF. Encorafenib showed good pharmacodynamics as single dose at 6mg/kg resulting in strong (75%) and sustained (>24h) decrease in p-MEK in PK/PD studies. Consistent with the in vitro data, Encorafenib can induce tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1mg/kg, but inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.85mL 0.37mL 0.19mL |
9.26mL 1.85mL 0.93mL |
18.52mL 3.70mL 1.85mL |
| 参考文献 |
|---|